Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Companyâs product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.

Employees

860

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 21:00:00 01/04/2025 BST			5-day change	1st Jan Change
131.87 ^USD	-0.04%		-.--%	+57.89%

04-15	J&J Boosts Outlook Despite Incoming Tariff Costs -- Update	DJ
04-15	J&J Increases Outlook After Beating 1Q Expectations	DJ

Capitalization	14.02B 12.02B 11.19B 10.44B 19.22B 1,205B 21.42B 135B 51.13B 563B 52.58B 51.5B 2,072B	P/E ratio 2023	-49.2x	P/E ratio 2024	-115x
Enterprise value	13.04B 11.18B 10.4B 9.71B 17.87B 1,121B 19.92B 125B 47.54B 523B 48.89B 47.88B 1,926B	EV / Sales 2023	13.8x	EV / Sales 2024	11.6x
Free-Float	96.14%	Yield 2023 *	-	Yield 2024	-

J&J Boosts Outlook Despite Incoming Tariff Costs -- Update	04-15	DJ
J&J Increases Outlook After Beating 1Q Expectations	04-15	DJ
Intra-Cellular Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	04-14	CI
Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from S&P Pharmaceuticals Select Industry Index	04-02	CI
Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from S&P TMI Index	04-02	CI
Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from S&P Global BMI Index	04-02	CI
Sector Update: Health Care Stocks Rise in Afternoon Trading	04-02	MT
Sector Update: Health Care	04-02	MT
Johnson & Johnson Completes Intra-Cellular Therapies Purchase	04-02	MT
J&J: about to acquire Intra-Cellular Therapies	04-02	CF
Johnson & Johnson Expects Lower Earnings Impact From Intra-Cellular Therapies Acquisition	04-02	MT
Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from NASDAQ Composite Index	04-01	CI
Johnson & Johnson Innovative Medicine completed the acquisition of Intra-Cellular Therapies, Inc. from a group of shareholders.	04-01	CI

Analyst recommendations: Block, Lucid, Celsius, Dun & Bradstreet, Sentinelone...	02-25
Mizuho Downgrades Intra-Cellular Therapies to Neutral From Outperform, Lowers Price Target to $132 From $140	02-24	MT
UBS Adjusts Price Target on Intra-Cellular Therapies to $132 From $87, Maintains Neutral Rating	02-05	MT
Canaccord Genuity Downgrades Intra-Cellular Therapies to Hold From Buy, Adjusts Price Target to $132 From $119	01-31	MT
Analysts recommendations: Accenture, Lockheed Martin, Hershey, Tapestry, Occidental Petroleum...	01-31

Intra-Cellular Therapies, Inc. Share Price

Equities

ITCI

US46116X1019

Pharmaceuticals

Valuation: Intra-Cellular Therapies, Inc.

Chart: Intra-Cellular Therapies, Inc.

Latest news: Intra-Cellular Therapies, Inc.

Last Transcript: Intra-Cellular Therapies, Inc.

Analysts' recommendations: Intra-Cellular Therapies, Inc.

Press Releases: Intra-Cellular Therapies, Inc.

News in other languages: Intra-Cellular Therapies, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Intra-Cellular Therapies, Inc.

Biopharmaceuticals

Financials

Company Profile

Income Statement and Estimates

INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI	02-25	BU
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders	02-25	BU
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results	02-24	AQ
Intra-Cellular: Q4 Earnings Snapshot	02-21	AQ
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results	02-21	AQ

MIDDAY BRIEFING - Unternehmen und Märkte -2-	04-15
J&J : acquisition imminente de Intra-Cellular Therapies	04-02
Intra Cellular Therapies : Leonteq Securities AG Übernahme/Fusion/Spin off (Sponsored Segment)	04-01
Où se situent les sociétés à forte croissance ?	02-20
Johnson & Johnson dépasse les attentes au T4 avec ses anticancéreux	01-22

Current year	80.82	131.98
1 year	70.9	131.98
3 years	42.01	131.98
5 years	17.26	131.98
10 years	6.75	131.98

Manager	Title	Age	Since
Sharon Mates CEO	Chief Executive Officer	72	28/08/2013
Sanjeev Narula DFI	Director of Finance/CFO	64	11/08/2024
Michael Halstead PSD	President	52	18/03/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
INTRA-CELLULAR THERAPIES, INC.	-0.04%	-.--%	+68.78%	+146.99%	14.02B
CSL LIMITED	+0.28%	-0.48%	-21.20%	-17.77%	76.69B
REGENERON PHARMACEUTICALS, INC.	+0.50%	+4.24%	-48.13%	-5.22%	59.99B
SAMSUNG BIOLOGICS CO.,LTD.	-1.42%	+4.20%	+26.61%	+25.24%	54.72B
UCB	+0.94%	+2.16%	+19.95%	+103.82%	37.99B
BIOGEN INC.	-0.82%	+0.18%	-42.14%	-37.95%	19.67B
INNOVENT BIOLOGICS, INC.	+1.80%	-4.87%	+101.47%	+125.58%	17.54B
ALTEOGEN INC.	+1.37%	+18.51%	+63.30%	+736.99%	17.06B
INCYTE CORPORATION	+2.03%	+2.24%	+9.93%	-11.88%	13.28B
MODERNA, INC.	-2.29%	+7.81%	-72.94%	-80.80%	13.01B
Average	+0.24%	+1.82%	+10.56%	+98.50%	32.4B
Weighted average by Cap.	+0.14%	+1.59%	-0.37%	+57.21%

	2023	2024
Net sales	464M 398M 371M 346M 636M 39.92B 709M 4.46B 1.69B 18.63B 1.74B 1.71B 68.61B	681M 584M 543M 507M 933M 58.53B 1.04B 6.54B 2.48B 27.32B 2.55B 2.5B 101B
Net income	-140M -120M -111M -104M -191M -12.01B -213M -1.34B -509M -5.6B -524M -513M -20.64B	-74.68M -64.02M -59.58M -55.62M -102M -6.42B -114M -718M -272M -3B -280M -274M -11.03B
Net Debt	-481M -412M -384M -358M -659M -41.35B -735M -4.62B -1.75B -19.3B -1.8B -1.77B -71.06B	-984M -844M -785M -733M -1.35B -84.6B -1.5B -9.46B -3.59B -39.48B -3.69B -3.61B -145B